Christine Siu
Chief Operating Officer chez BRIDGEBIO PHARMA, INC.
Fortune : - $ au 31/03/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jonathan Fox | M | 67 | 8 ans | |
Eric Aguiar | M | 62 |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | 15 ans |
Ali Satvat | M | 46 | 8 ans | |
Alexander Mayweg | M | 49 |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund.
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | 7 ans |
Uma Sinha | M | 67 | 11 ans | |
Neil Kumar | M | 45 | 9 ans | |
Aleksandra Rizo | M | 49 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Markus Warmuth | M | 53 | 4 ans | |
Jeffrey Hatfield | M | 66 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 4 ans |
Laura Shawver | M | 66 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | 3 ans |
Andrew Lo | M | 63 | 9 ans | |
Fredrik Wiklund | M | 53 |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | - |
Charles Homcy | M | 75 | 9 ans | |
Francis McCormick | M | 73 | 9 ans | |
Andrew Schiff | M | 58 | 4 ans | |
Richard Heyman | M | 66 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 7 ans |
Kimberly Blackwell | M | 55 | 4 ans | |
Jan Skvarka | M | 57 | 1 ans | |
Ronald Daniels | M | 64 | 4 ans | |
Brian Stephenson | M | 43 | 6 ans | |
Sharon Townson | M | 49 | 4 ans | |
Michael Rosenzweig | M | - |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | - |
Hannah Valantine | M | 72 | 3 ans | |
Vijaya R. Pattabiraman | M | - |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | - |
Andrea Ellis | F | 38 | 3 ans | |
John Castle | M | 54 | 4 ans | |
Jennifer Champoux | F | - | 3 ans | |
Joshua Resnick | M | 49 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | - |
Thomas Woiwode | M | 52 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | 6 ans |
Fred Hassan | M | 78 | 3 ans | |
Randal Scott | M | 66 | 4 ans | |
Richard Scheller | M | 70 | - | |
Douglas Dachille | M | 59 | 3 ans | |
Jacob Chacko | M | 45 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland.
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | 3 ans |
Chandra Paul Leo | M | 53 | 4 ans | |
Benjamin Cravatt | M | 54 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 10 ans |
Anthony Manning | M | 62 | 1 ans | |
Ali Behbahani | M | 47 | 4 ans | |
Thomas Trimarchi | M | - | 3 ans | |
Vikram Bali | M | - | - | |
Christine Roth | F | - |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Philip Nickson | M | 45 | 3 ans | |
Leena Gandhi | M | 53 |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The private company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | 2 ans |
James Momtazee | M | 52 | 8 ans | |
Eric Michael David | M | 56 | - | |
Xiaohu Deng | M | - |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Lisa Percival | F | - |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Todd Kinsella | M | 54 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 7 ans |
Christian Rommel | M | - |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Jennifer Cook | F | 58 | 5 ans | |
Filip Janku | M | 50 | 3 ans | |
Jon Wigginton | M | 62 |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | - |
Adora Ndu | M | 43 | 2 ans | |
Owen Wallace | M | 55 | 3 ans | |
Matthew Outten | M | 49 | 5 ans | |
Patricia Allen | F | 62 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 3 ans |
Marianne de Backer | M | 55 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Stefan Oelrich | M | 55 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | - |
Michael Rapé | M | - | 4 ans | |
Christine Seidman | M | 71 | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
John J. Schembri | M | 62 | - | |
Mark Goldsmith | M | 62 | 2 ans | |
Stephen Bardin | M | 34 | 3 ans | |
Cameron Turtle | M | 34 | - | |
Franco Valle | M | 43 | 3 ans | |
Ted Love | M | 65 | 9 ans | |
William Lis | M | 59 | 3 ans | |
Joshua Lehrer-Graiwer | M | 50 | 7 ans | |
Brenton Saunders | M | 56 | 3 ans | |
Raj Shah | M | 46 | 2 ans | |
Wonpyo Yun | M | - | 1 ans | |
Paul Herzich | M | 46 | 1 ans | |
Shannon Stone | F | - | 2 ans | |
Min Wang | M | - | 1 ans | |
Katherine Yau | F | - | 1 ans | |
Grace Rauh | F | - | - | |
Ching Yau Yi | F | - | 3 ans | |
Emily Cox | F | - | 1 ans | |
Michael Henderson | M | 34 | 6 ans | |
Meg M. Silverman | F | - |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | 1 ans |
Camille Landis | F | - | - | |
R. Session | M | 45 | 1 ans | |
Jullian Jones | M | - | - | |
Brian Stolz | M | 48 | 1 ans | |
Anya Schiess | F | - |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | 5 ans |
Kim Graham | M | - | - | |
Jason M. Brown | M | 52 |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | 9 ans |
Ajim Tamboli | M | 47 | 3 ans | |
Ho Young Huh | M | 54 | - | |
Karen M. Boezi | F | - |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance Thomas, McNerney & Partners LLC (Thomas McNerney & Partner) is a venture capital subsidiary of the Coral Group Inc founded in 1998. The firm is headquartered in Minneapolis, Minnesota. | - |
Kristina Burow | F | 50 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | 4 ans |
Kevin Starr | M | 61 | 4 ans | |
Lee Rauch | F | - | - | |
Dan Mulreany | M | - | 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 76 | 80,85% |
Suisse | 7 | 7,45% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Christine Siu
- Réseau Personnel